Chrysalin
Tested in peopleIt has been tested in people, but it is not an approved medicine. The studies are usually small.
Also called TP-508 / Rusalatide acetate
A short peptide copied from thrombin, tested in people for bone and wound healing.
The basics
- What is it?
- Chrysalin is a 23-amino-acid piece of thrombin, a blood clotting protein. It has been through human trials for fracture repair and diabetic foot ulcers.
Can a doctor prescribe this?
No. Pharmacies are not on record as being allowed to make this into a medicine.
The FDA has not approved this as a medicine.
Not FDA approved and not on the U.S. compounding list. A doctor cannot prescribe it.
Official status: Not on the 503A bulks list. Checked 2026-08-04.
Lab suppliers we list: 2
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
No dosing information has been published in the research indexed here.
- Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study.
Study in people
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2007
- Thrombin peptide TP508 stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues.
Lab dish study
The Journal of bone and joint surgery. American volume · 2006
- Thrombin peptide (TP508) treatment of rat growth plate cartilage cells promotes proliferation and retention of the chondrocytic phenotype while blocking terminal endochondral differentiation.
Lab dish study
Journal of cellular physiology · 2005
- Novel regenerative peptide TP508 mitigates radiation-induced gastrointestinal damage by activating stem cells and preserving crypt integrity.
Laboratory investigation; a journal of technical methods and pathology · 2015
- Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair?
Expert opinion on pharmacotherapy · 2008
- TP508 (Chrysalin) reverses endothelial dysfunction and increases perfusion and myocardial function in hearts with chronic ischemia.
Journal of cardiovascular pharmacology and therapeutics · 2008
- Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology · 2007
- Technology evaluation: Chrysalin (Orthologic).
Current opinion in molecular therapeutics · 2005
- Repair of rabbit segmental defects with the thrombin peptide, TP508.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2004
- Blood pumps: technologies and markets in transformation.
Artificial organs · 2001
- In-silico evaluation of Oroxylum indicum vent compounds in the plausible treatment and prevention of nasopharyngeal cancer.
Review of earlier work
Journal of Ayurveda and integrative medicine · 2024
- The Role of Recombinant Proteins and Growth Factors in the Management of Diabetic Foot Ulcers: A Systematic Review of Randomized Controlled Trials.
Review of earlier work
Journal of diabetes research · 2020